Compensation Programs for Potential COVID-19 Vaccine Injuries [Updated October 20, 2021]   [open pdf - 860KB]

From the Document: "More than 200 million [hyperlink] Americans have received one or more doses of a Coronavirus Disease 2019 (COVID-19) vaccine, along with billions [hyperlink] of people worldwide. The Food and Drug Administration's (FDA's) emergency use authorizations for the Pfizer-BioNTech [hyperlink], Moderna [hyperlink], and Johnson & Johnson [hyperlink] COVID-19 vaccines were based on months-long clinical trials (including safety monitoring) of each vaccine, involving tens of thousands of participants. [...] The most common [hyperlink] side effects of COVID-19 vaccines are mild--such as local pain around the injection side, tiredness, or fever--and usually resolve within a few days. As with most vaccines, however, a very small [hyperlink] percentage of inoculated individuals experience serious adverse reactions to a COVID-19 vaccine. For example, approximately [hyperlink] two to five people per million receiving mRNA [messenger ribonucleic acid] COVID-19 vaccines experience anaphylaxis, a severe allergic reaction, following vaccination. (For this reason, the CDC [Centers for Disease Control and Prevention] recommends [hyperlink] that all individuals be monitored for at least 15 minutes following their vaccinations, and that all vaccination sites have epinephrine available for treatment of anaphylaxis.) Other serious adverse events reported following vaccination, such as myocarditis [hyperlink] and Guillain-Barré Syndrome [hyperlink], are similarly rare [hyperlink] and may be associated with COVID-19 vaccines."

Report Number:
CRS Legal Sidebar, LSB1058
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Media Type:
Help with citations